The China Center for Drug Evaluation (CDE) website has indicated that Japan-based Eisai (TYO: 4523) has filed lemborexant, marketed under the trade name Dayvigo, for approval with the National Medical Products Administration (NMPA) in China. Lemborexant is a dual orexin receptor antagonist that competitively binds to two types of orexin receptors, OX1R and OX2R, to inhibit the neurotransmission of orexin and regulate the sleep-wake rhythm.
The drug has already received marketing approval in the US and Japan in June and July 2020, respectively, for the treatment of insomnia patients. Lemborexant is also awaiting a regulatory decision in Hong Kong, highlighting its potential as a treatment for sleep disorders in the region.- Flcube.com
